Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC add-on in refractory MDD with inflammation
NCT02972398Unknown
- Sponsor
- Tianjin Anding Hospital
- Start
- Sep 2015
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in major depressive disorder (MDD) comparing NAC group with Placebo group (2 arms). Primary endpoint: Hamilton Depression Rating Scale-17 at 12 weeks. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02972398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972398.